Tilray | TRLY - Ebit

金融业

USD

USD 2.1B

现金及等价物

USD 264.83M

USD 164.37M

USD 729.32M

USD 259.32M

USD 640.95M

USD -20.01M

USD 8.37M

USD 2.84K

EPS每股收益

USD -0.41

股本和储备

USD 1.58B

USD 57.47M

债务利息支出

USD 6.7M

USD 12.83M

USD 268.59M

USD 5.63B

USD -44.93M

USD 237.52M

USD -20.01M

普通股股本

USD 116.52M

11.57

USD -39.96M

USD 217.51M

销售和管理费用

USD 24.85M

USD 282.79M

贸易债权人

USD 114.5M

应收帐款人

USD 109.07M

	Ebit	更改		日
Acasti Pharma	USD -3.7M		1.13M	2024-12
Akebia Therapeutics	USD -5.45M		9.4M	2025-12
Alaunos Therapeutics	USD -1.19M		148K	2025-09
Aurora Cannabis	CAD -35.79M		8.96M	2025-12
Avita Medical	AUD -10.39M		1.72M	2025-12
Canopy Growth	CAD -12.66M		1.64M	2025-12
Cronos Group	USD -1.45M		5.61M	2026-03
Dianthus Therapeutics	USD -69.54M		29.25M	2025-12
Divis Laboratories Ltd	INR 7.72B		30M	2025-12
Ionis Pharmaceuticals	USD -118M		97M	2026-03
IQVIA Holdings	USD 565M		2.11B	2026-03
Knight Therapeutics	CAD 6.21M		3.27M	2025-12
Moderna	USD -1.39B		531M	2026-03
Organigram Holdings	CAD -20.13M		7.92M	2025-12
Organon & Co	USD -27M		415M	2025-12
Revvity	USD 82.77M		63.06M	2026-03
Tectonic Therapeutic	USD -21.52M		374K	2025-12
Tilray	USD -20.01M		9.34M	2025-09
Viatris	USD -20.2M		137.3M	2026-03
Xeris Pharmaceuticals	USD 16.77M		8.88M	2025-12
Zealand Pharma A/S	-707.05M		245.73M	2025-12